Dawn Halkuff Net Worth

The estimated Net Worth of Dawn Halkuff is at least $176 mil dollars as of 20 November 2023. Ms. Halkuff owns over 5,410 units of Xeris Biopharma Inc stock worth over $15,473 and over the last 6 years she sold XERS stock worth over $0. In addition, she makes $160,360 as Independent Director at Xeris Biopharma Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Halkuff XERS stock SEC Form 4 insiders trading

Dawn has made over 1 trades of the Xeris Biopharma Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently she bought 5,410 units of XERS stock worth $9,954 on 20 November 2023.

The largest trade she's ever made was buying 5,410 units of Xeris Biopharma Inc stock on 20 November 2023 worth over $9,954. On average, Dawn trades about 676 units every 0 days since 2019. As of 20 November 2023 she still owns at least 5,410 units of Xeris Biopharma Inc stock.

You can see the complete history of Ms. Halkuff stock trades at the bottom of the page.

Dawn Halkuff biography

Dawn Halkuff serves as Independent Director of the Company. Since 2016, Ms. Halkuff has served as the chief commercial officer of TherapeuticsMD, Inc. Prior to that, Ms. Halkuff held numerous senior level positions at Pfizer, Inc. and the Pfizer Consumer Healthcare Wellness Organization and was a member of its Consumer Global Leadership Team, including roles as senior vice president, global wellness, vice president, women’s health sales and marketing and senior director, women’s health products. Prior to that, Ms. Halkuff was the commercial lead for sales and marketing of the Pfizer’s Women’s Health Division. From 2005 to 2010, Ms. Halkuff was head of global innovation at Weight Watchers International.

What is the salary of Dawn Halkuff?

As the Independent Director of Xeris Biopharma Inc, the total compensation of Dawn Halkuff at Xeris Biopharma Inc is $160,360. There are 10 executives at Xeris Biopharma Inc getting paid more, with Paul Edick having the highest compensation of $4,307,640.

How old is Dawn Halkuff?

Dawn Halkuff is 49, she's been the Independent Director of Xeris Biopharma Inc since 2018. There are 18 older and 1 younger executives at Xeris Biopharma Inc. The oldest executive at Xeris Biopharma Holdings Inc is Jeffrey Sherman, 65, who is the Independent Director.

What's Dawn Halkuff's mailing address?

Dawn's mailing address filed with the SEC is C/O XERIS BIOPHARMA HOLDINGS, INC., 1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL, 60607.

Insiders trading at Xeris Biopharma Inc

Over the last 6 years, insiders at Xeris Biopharma Inc have traded over $2,845,230 worth of Xeris Biopharma Inc stock and bought 2,912,235 units worth $31,442,123 . The most active insiders traders include Group, Llc Green Jeremy Red..., James E Deerfield Mgmt L.P...., eGarheng Kong. On average, Xeris Biopharma Inc executives and independent directors trade stock every 46 days with the average trade being worth of $197,048. The most recent stock trade was executed by John P. Schmid on 12 August 2024, trading 4,515 units of XERS stock currently worth $10,159.

What does Xeris Biopharma Inc do?

xeris aspires to break through this restraint by developing ultra-low volume, ready-to-use biotherapeutics delivered through patient-friendly injectable devices. products built on our xeriject technologies could potentially ease the pain of injections for hundreds of millions of patients.

Complete history of Ms. Halkuff stock trades at Xeris Biopharma Inc

Xeris Biopharma Inc executives and stock owners

Xeris Biopharma Inc executives and other stock owners filed with the SEC include:

• Paul Edick,
  Chairman of the Board, Chief Executive Officer
• John Shannon,
  President, Chief Operating Officer
• Paul R. Edick,
  Chairman & CEO
• Barry Deutsch,
  Chief Financial Officer
• John P. Shannon,
  Pres, COO & Director
• Beth Hecht,
  Senior Vice President, General Counsel, Corporate Secretary
• Beth P. Hecht J.D.,
  Sr. VP, Gen. Counsel, Corp. Sec. & Director
• John Schmid,
  Lead Independent Director
• BJ Bormann,
  Independent Director
• Marla Persky,
  Independent Director
• Jeffrey Sherman,
  Independent Director
• Dawn Halkuff,
  Independent Director
• Mark Thierer,
  Independent Director
• Kenneth Johnson,
  Senior Vice President, Clinical Development, Regulatory, Quality Assurance and Medical Affairs
• Steven Prestrelski,
  Co-Founder, Chief Scientific Officer
• Dr. Steven J. Prestrelski MBA, Ph.D.,
  Co-Founder & Chief Scientific Officer
• Kevin McCulloch,
  Sr. VP of Global Operations & Bus. Devel.
• Dr. Kenneth E. Johnson Pharm. D., Pharm.D.,
  Sr. VP of Clinical Devel., Regulatory, Quality Assurance & Medical Affairs
• Barry M. Deutsch,
  Exec. Officer
• Allison Wey,
  Sr. VP of Investor Relations & Corp. Communications
• Steven M. Pieper,
  Chief Financial Officer
• Dr. Steven J. Prestrelski,
  Co-Founder & Chief Scientific Officer
• Group, Llc Green Jeremy Red...,
  
• James E Deerfield Mgmt L.P....,
  
• Partners, Ltd.Palmetto Part...,
  
• Barbara Jean Anne Bormann K...,
  Director
• Jonathan Rigby,
  Director
• Kevin Mc Culloch,
  See Remarks
• Steven Pieper,
  See Remarks
• John Johnson,
  Director
• Garheng Kong,
  Director
• Ricki Louise Fairley,
  Director